This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): PPL-100
Description: PPL-100 is a protease inhibitor which binds specifically to HIV-1 protease, the enzyme that allows the virus to finalize its maturation, and therefore results in the formation of immature and non-infectious viral particles.
Deal Structure: In October 2006, Ambrilia and Merck entered into an exclusive licensing agreement granting Merck - through an affiliate - the worldwide rights to PPL-100. In return, Ambrilia receives an upfront licensing fee of $US 17 million on signing and is eligible for cash payments totaling up to $US 215 million upon successful completion of development, clinical, regulatory and sales milestones, and royalties on all future product sales. Once the Phase I repeat dose pharmacokinetic study is completed, Merck will assume all subsequent development costs related to PPL-100.
In June 2009, Ambrilia announced that it settled with Merck Sharp and Dohme Research Limited and Merck (Merck) the arbitration pending before the International Court of Arbitration of the International Chamber of Commerce that concerned their Exclusive License Agreement of October 12, 2006 and a November 14, 2003 Confidentiality Agreement (the Arbitration). The terms of the settlement provide for the termination of the...See full deal structure in Biomedtracker
Partners: Ambrilia Biopharma, Inc.
Pink Sheet Regulatory Twitter Goes '#Rogue' With AltFDA
Pink Sheet Weekly Trademark Review Dec. 27, 2016
Additional information available to subscribers only: